54.14
price up icon0.97%   0.52
pre-market  Pre-market:  55.99   1.85   +3.42%
loading
Keros Therapeutics Inc stock is traded at $54.14, with a volume of 379.61K. It is up +0.97% in the last 24 hours and down -11.61% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$53.62
Open:
$53.53
24h Volume:
379.61K
Relative Volume:
1.07
Market Cap:
$2.19B
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-11.93
EPS:
-4.54
Net Cash Flow:
$-146.15M
1W Performance:
-14.16%
1M Performance:
-11.61%
6M Performance:
+3.38%
1Y Performance:
+80.47%
1-Day Range:
Value
$52.63
$54.87
1-Week Range:
Value
$52.63
$63.51
52-Week Range:
Value
$27.31
$73.00

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
Name
Keros Therapeutics Inc
Name
Phone
617-314-6297
Name
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
Employee
160
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
KROS's Discussions on Twitter

Compare KROS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
KROS 54.14 2.19B 0 -168.05M -146.15M -4.54
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-21-24 Initiated William Blair Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Jul-31-23 Initiated Wedbush Outperform
Jul-26-23 Initiated BofA Securities Buy
Feb-14-23 Initiated Cowen Outperform
Oct-18-22 Initiated Truist Buy
Jul-26-22 Initiated BTIG Research Buy
Dec-08-20 Reiterated H.C. Wainwright Buy
May-04-20 Initiated H.C. Wainwright Buy
May-04-20 Initiated Jefferies Buy
May-04-20 Initiated Piper Sandler Overweight
May-04-20 Initiated SVB Leerink Outperform
View All

Keros Therapeutics Inc Stock (KROS) Latest News

pulisher
Nov 16, 2024

Long Term Trading Analysis for (KROS) - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 11, 2024

What is Leerink Partnrs’ Estimate for KROS FY2024 Earnings? - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Equities Analysts Offer Predictions for KROS FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

What is HC Wainwright's Estimate for KROS FY2024 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Decreases Earnings Estimates for Keros Therapeutics - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for KROS Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Has Negative Outlook of KROS FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Equities Analysts Cut Earnings Estimates for KROS - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 Earnings Estimate for KROS Issued By HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Jefferies Financial Group - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023) - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Brokers Offer Predictions for KROS Q3 Earnings - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Q3 Earnings Estimate for KROS Issued By Wedbush - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Interesting KROS Put And Call Options For April 2025 - Nasdaq

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Reaffirms Buy Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Brokers Set Expectations for KROS Q4 Earnings - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

KROSKeros Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at Guggenheim Conference - TipRanks

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Brokers Issue Forecasts for KROS Q4 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Wedbush Upgrades Keros Therapeutics (NASDAQ:KROS) to Strong-Buy - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Jefferies starts Keros Therapeutics with buy, $107 target By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

(KROS) Proactive Strategies - Stock Traders Daily

Nov 05, 2024
pulisher
Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Nov 05, 2024
pulisher
Nov 03, 2024

Emerald Advisers LLC Acquires Shares of 155,545 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $89.11 - Defense World

Nov 01, 2024
pulisher
Oct 30, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Analysts Offer Predictions for KROS FY2024 Earnings - Defense World

Oct 29, 2024
pulisher
Oct 28, 2024

Assenagon Asset Management S.A. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Cantor Fitzgerald Weighs in on KROS FY2024 Earnings - Defense World

Oct 28, 2024
pulisher
Oct 28, 2024

Brokers Set Expectations for KROS FY2024 Earnings - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World

Oct 26, 2024
pulisher
Oct 25, 2024

(KROS) Trading Signals - Stock Traders Daily

Oct 25, 2024
pulisher
Oct 25, 2024

Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Cantor Fitzgerald initiates coverage on Keros Therapeutics shares with Overweight rating By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS) - MarketBeat

Oct 24, 2024
pulisher
Oct 16, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Scotiabank - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics appoints new Chief Medical Officer - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics, Inc. Appoints Yung H. Chyung as Chief Medical Officer, Effective as of November 1, 2024 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 16, 2024

Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Declines By 13.7% - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Objective long/short (KROS) Report - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 09, 2024

Renaissance Technologies LLC Invests $654,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Oct 09, 2024
pulisher
Oct 09, 2024

Renaissance Technologies LLC Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Marshall Wace LLP Has $1.02 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Dimensional Fund Advisors LP Sells 3,691 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Oct 08, 2024
pulisher
Oct 07, 2024

19,832 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Squarepoint Ops LLC - Defense World

Oct 07, 2024
pulisher
Oct 07, 2024

Squarepoint Ops LLC Buys New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Oct 07, 2024

Keros Therapeutics Inc Stock (KROS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):